Hana Biosciences to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference

Hana Biosciences (AMEX:HBX), a South San Francisco-based
biopharmaceutical company focused on advancing cancer care, will
present at the Rodman & Renshaw Techvest 7th Annual Healthcare
Conference, at 9:45 AM EST in the Holmes II room on November 8, 2005.
The forum is being held at the New York Palace Hotel, 455 Madison
Avenue, New York, New York. A web cast of the presentation may be
accessed at www.hanabiosciences.com/investor-iw.html and will be
archived for a period of 90 days.

   About Hana Biosciences

   Hana Biosciences, Inc. (AMEX:HBX) is a South San Francisco,
CA-based biopharmaceutical company that acquires, develops, and
commercializes innovative products to advance cancer care. The company
is committed to creating value by building a world-class team,
accelerating the development of lead product candidates, expanding its
pipeline by being the alliance partner of choice, and nurturing a
unique company culture. Additional information on Hana Biosciences can
be found at www.hanabiosciences.com.

   This press release contains forward-looking statements that
involve risks and uncertainties that could cause Hana's actual results
to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions that are
subject to risks and uncertainties, which could cause actual outcomes
and results to differ materially from these statements. Among other
things, there can be no assurances that any of Hana's development
efforts relating to its product candidates will be successful. Other
risks that may affect forward-looking information contained in this
press release include the possibility of being unable to obtain
regulatory approval of Hana's product candidates, the risk that the
results of clinical trials may not support Hana's claims, Hana's
reliance on third party researchers to develop its product candidates
and its lack of experience in developing pharmaceutical products.
Additional risks are described in the company's Annual Report on Form
10-KSB for the year ended December 31, 2004. Hana assumes no
obligation to update these forward-looking statements, except as
required by law.